Full-Time

Director – Clinical Science

Recursion

Recursion

501-1,000 employees

Data-driven drug discovery platform leveraging datasets

No salary listed

Salt Lake City, UT, USA + 1 more

More locations: New York, NY, USA

Remote

Remote in the United States with occasional travel.

Category
Biology & Biotech (1)

Get referred to Recursion

See people who can refer or advise you

Requirements
  • 5-7+ years as a Clinical Scientist in a pharmaceutical or biotech company
  • Prior experience in early phase 1-2 oncology studies is required
Responsibilities
  • Create – Serve as the authoring lead on multiple clinical documents. Recursion is moving away from the use of Medical Writers and relying more heavily on the Clinical Scientist and Medical Director to author IND and study-specific documents. While this will not refer to manuals, it does encompass Clinical documents and site/agency interactions.
  • Collaborate - Work with highly dynamic teams where your role will range from leading and owning decisions or timelines to being a key contributor whose experience and insight are relied upon to advance the task at hand.
  • Drive & Deliver – You will be primarily responsible for the quality of your study data. This will include reviewing (Medical Monitoring); issuing, reviewing, and closing queries; reviewing TLFs, summarizing data throughout the trial, and presenting the data to management when requested. You will also be required to present the protocol procedures and Site Initiation Visits both in-person and virtually.
  • Prioritize – Given the nature of Recursion, you will be required to support multiple early-phase (1-2) studies simultaneously. This will require time management and organizational skills.
Desired Qualifications
  • Experience with hematologic malignancies is preferred

Recursion uses hardware, software, and data to accelerate drug discovery in the TechBio space, running thousands of wet-lab experiments weekly to profile genes and compounds across many cell types. It combines a massive proprietary dataset (about 50 petabytes) with a powerful computing platform, BioHive 1, to map billions of gene–compound relationships and generate actionable drug candidates. Its approach blends high-throughput experimentation with large-scale data science to create learning loops and partnerships with pharmaceutical companies, research institutions, and healthcare providers. Its goal is to decode biology at scale and discover and commercialize medicines that can improve patient lives.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Salt Lake City, Utah

Founded

2013

Get referred to Recursion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • REC-4881 achieved 53% median polyp reduction at Week 25, validating the AI platform clinically.
  • FDA Fast Track and Orphan Drug designations accelerate the regulatory pathway for REC-4881 in FAP.
  • $665.2 million cash runway supports operations into early 2028 despite recent revenue declines.

What critics are saying

  • Roche partnership completion caused a 56% Q1 2026 revenue drop, exposing acute customer concentration risk.
  • $378.3 million negative free cash flow in FY 2025 creates existential dilution risk if Phase 3 fails.
  • Schrödinger's $255.9 million revenue and positive cash flow expose Recursion's inferior unit economics.

What makes Recursion unique

  • Recursion OS integrates biology, chemistry, automation, and AI to industrialize drug discovery at scale.
  • The company generates 50 petabytes of proprietary data via 2.2 million weekly wet lab experiments.
  • BioHive 1 supercomputer processes six trillion gene-compound relationships within the custom Recursion Map.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Hybrid Work Options